

WORKSHOP PROGRAMME

26 January 2022 (Day 1)*	27 January 2022 (Day 2)*
<p>13:30-14:00 Welcome & Introduction to Workshop (30min) <i>Chair: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer Institute for Cell Therapy and Immunology (IZI))</i> <i>Chair: Jonathan Moggs (imSAVAR Project Leader, Novartis Institutes for Biomedical Research (NIBR))</i></p> <p>13:30-13:40 imSAVAR overview (10min) <i>Speaker: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI)</i> <i>Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)</i></p> <p>13:40-13:50 Patient engagement in early drug development (10min) <i>Speaker: Jan Geissler (WECAN Chair, CML Advocates Network (CML))</i></p> <p>13:50-14:00 An imSAVAR model grading system (10min) <i>Speaker: Scott Wagers (BioSci Consulting)</i></p> <p>14:00-14:40 Adverse events (AEs) of immuno-oncology therapies in detail (30min) <i>Speaker: Michel Obeid (Centre Hospitalier Universitaire Vaudois (CHUV))</i> Q & A (10min)</p> <p>14:40-15:10 Nonclinical assessments for immuno-oncology therapies in detail (30min) <i>Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)</i> Q & A (10min)</p>	<p>14:00-14:40 Patient preferences in drug development – PREFER approach (30min) <i>Speaker: Conny Berlin (PREFER Project Leader, Novartis)</i> Q & A (10min)</p> <p>14:40-16:10 How to integrate patient preferences in the imSAVAR Model Grading System? (90min) <i>Moderator: Scott Wagers</i></p> <p>14:40-14:55 Scene setting (15min) <i>Speaker: Scott Wagers (BioSci Consulting)</i></p> <p>14:55-16:10 Panel discussion (75min) <i>Panelists:</i></p> <ul style="list-style-type: none"> ▪ Gilliosa Spurrier-Bernard (MPNE) ▪ Bettina Ryll (MPNE, Horizon Europe Cancer Mission Board Member) ▪ Alfonso Aguarón (LuCE) ▪ Jan Geissler (WECAN Chair, CML) ▪ Michael Hudecek (Universitätsklinikum Würzburg (UKW)) ▪ Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI) ▪ Alexander Mosig (Universitätsklinikum Jena) ▪ Peter Loskill (UKT) (Tübinger Universitätsklinikum) ▪ Jonathan Moggs (imSAVAR Project Leader, NIBR)) ▪ Ekaterina Breous-Nystrom (Roche) ▪ Birgit Fogal (Boehringer Ingelheim) ▪ Conny Berlin (IMI PREFER Project Leader, Novartis) <p>16:10-16:30 Concluding remarks (20min) <i>Speaker: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI)</i> <i>Speaker: Jonathan Moggs (imSAVAR Project Leader, NIBR)</i></p>
15:10-15:30 Coffee Break	
<p>15:30-16:50 Patient perspectives on immune-related adverse events (irAEs) (80min) <i>Chair: Ulrike Köhl (imSAVAR Project Coordinator, Fraunhofer IZI)</i></p> <p>15:30-15:50 Patient perspectives on irAEs attributed to melanoma (10min) <i>Speaker: Gilliosa Spurrier-Bernard (Melanoma Patients Network Europe (MPNE))</i> <i>Speaker: Bettina Ryll, ((Melanoma Patients Network Europe (MPNE)), Horizon Europe Cancer Mission Board Member)</i> Q & A (10min)</p> <p>15:50-16:10 Patient perspectives on irAEs attributed to lung cancer (10min) <i>Speaker: Alfonso Aguarón (Lung Cancer Europe (LuCE))</i> Q & A (10min)</p> <p>16:10-16:30 Patient perspectives on irAEs attributed to leukaemias (10min) <i>Speaker: Jan Geissler (WECAN Chair, CML)</i> Q & A (10min)</p> <p>16:30-16:50 Patient perspectives on irAEs attributed to myeloma (10min) <i>Speaker: Hans Scheurer (Myeloma Patient Europe)</i> Q & A (10min)</p> <p>16:50-17:00 Wrap-up of Day 1 and Overview of Day 2 programme (10min)</p>	

*The Workshop Programme is subject to change. A recording of the Workshop will be available after the event. All timing are in CET.